
Dr. Schwartz became interested in heterogeneous systems by studying the diversity and selection of the immune receptor repertoire during his Ph.D research at Drexel University (2011-2016). He subsequently joined the Perelman School of Medicine at the University of Pennsylvania as a postdoctoral researcher, where he studied heterogeneous responses to strong selective pressure in cancer by developing and applying new methods and algorithms to elucidate drug response (2016-2021). He has designed methods including the integration of different data modalities such as transcriptomes and proteomes to discover pan-cancer biomarkers as well as techniques to characterize and quantify new classes of diverse mutations at the nucleotide level in acute myeloid leukemia. More recently, he has leveraged single-cell technologies to deconvolve resistance to targeted therapy in T-cell acute lymphoblastic leukemia.